AMLN

AMLN Articles

Diabetes is becoming an epidemic in the U.S. and the Western World.  The ties to obesity are often direct, so the potential treatments are often directly tied as well.  We did a recent dig down for...
The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis...
These are some of the top stories affecting key drug and biotech stocks that are covered with more in-depth details and analysis this morning at BioHealthInvestor.com: Amgen Inc’s (Nasdaq:...
Billionaire and activist investor Carl Icahn has made some  large changes to his portfolio holdings.  He and Icahn Capital, L.P. have not been immune to the market sell-off as you have seen in his...
These are some of the top pre-market analyst downgrades and cautious calls we are seeing this Thursday morning: Affymetrix (AFFX) Cut to Underweight at JPMorgan. Air Products (APD) Cut to Neutral at...
These are some of the top pre-market downgrades and cautious calls we have seen from Wall Street analysts this Wednesday morning: Amylin Pharmaceuticals (AMLN) Cut to Sell at Canaccord Adams. Biogen...
Amylin Pharmaceuticals, Inc., (NASDAQ: AMLN) has been a battered biotech lately.  But shares have just now gotten back above the single-digit threshold and are up more than 80% from recent lows. ...
Below are some of the top early bird analyst downgrades we have seen early this morning with more than two hours to the open: Advantage Energy (AAV) Cut to Sector Perform at CIBC. Amylin...
Ford (F) Oil moves up. Drops to $4.25 from a 52-week high of $9.24. Nexmed (NEXM) Drug trial problems. Falls to $.23 from a 52-week high of $.1.87. Cell Genesys (CEGE) Drug trial problems. Plunges to...
It is getting pretty thin in analyst coverage as we get closer to Labor Day, but these are the upgrades and downgrades we are seeing this Wednesday morning: Exponent (EXPO) Started as Buy at...
The National Funeral Directors Association must be sending “thank you” cards to Eli Lilly (LLY) and it partner Amylin (AMLN). Together, the companies developed and market diabetes drug Byetta....
Amylin (AMLN) CEO Dan Bradbury earned a base salary of almost $560,000 last year according to the company proxy. He will probably do as well in 2008. During the last twelve months, shares in the...
If there wasn’t enough already wrong with the FDA drug approval process, diabetes drug Byetta, created for patients by Elli Lilly (LLY) and Amylin Pharmaceuticals (AMLN) is killing more people. The...
These are ten of the analyst calls we are focusing on this Wednesday morning: Alaska Communications (NASDAQ: ALSK) Raised to Buy at Banc Of America Securities. Amylin Pharmaceuticals (NASDAQ: AMLN)...
Carl Icahn is a billionaire financier, activist, and investor.  Most think of Icahn as an activist investor that wants to get inside and drive value without having to acquire the whole company to...